Axsome Therapeutics, Inc. (AXSM)

Over the past six months, Axsome Therapeutics' stock has experienced significant upward momentum. Key events impacting the stock price include the FDA approval of Auvelity for Alzheimer's agitation, the Q1 2026 earnings report, insider selling activity, FDA fast-track designation for an Alzheimer's drug and narcolepsy filing backing, and the Symbravo FDA approval investor event.

Axsome Therapeutics' products, which target chronic central nervous system disorders, generally do not exhibit strong demand seasonality. However, there can be some seasonal market factors that influence prescription trends. Axsome noted "market seasonality headwinds at the beginning of the calendar year" in its Q1 2025 earnings call. There might be slight fluctuations in prescription volumes at certain times of the year, possibly related to patient deductibles resetting or holiday periods impacting doctor visits.

Axsome Therapeutics, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing novel therapies for central nervous system (CNS) disorders. Its commercial product portfolio includes Auvelity for major depressive disorder and Alzheimer's disease agitation, Sunosi for excessive daytime sleepiness, and Symbravo for migraine. The company also has a pipeline of investigational candidates, including AXS-05, AXS-12, and AXS-14.

Axsome Therapeutics, Inc. is headquartered in New York, New York, United States. The company develops and delivers novel therapies for CNS disorders in the United States and has international subsidiaries in Australia, Ireland, Delaware, Malta and Canada.

Axsome Therapeutics' brand reputation is influenced by its progress in drug development and commercialization, particularly within the CNS disorder space. The FDA approval of Auvelity for Alzheimer's agitation is a significant positive event. However, the Q1 2026 earnings miss, FDA refusal to accept NDA for AXS-14, and widening losses could present challenges or mixed perceptions. Overall, the recent FDA approval for Auvelity in Alzheimer's agitation and continued revenue growth for its commercial products likely bolster Axsome's reputation.

Axsome Therapeutics' ownership is a mix of institutional, individual, and retail holdings. Institutional investors collectively hold a dominant percentage of the company's shares. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., and Price T Rowe Associates Inc /md/. The largest individual shareholder is Dr. Herriot Tabuteau, the founder, Chief Executive Officer, and Chairman of Axsome Therapeutics.